Results 11 to 20 of about 86,105 (313)

Differential effects of cotreatment of the antibiotic rifampin with host-directed therapeutics in reducing intracellular Staphylococcus aureus infection [PDF]

PeerJ, 2020
Background Chronic infection by Staphylococcus aureus drives pathogenesis in important clinical settings, such as recurrent pulmonary infection in cystic fibrosis and relapsing infection in osteomyelitis. Treatment options for intracellular S.
Melissa D. Evans, Robert Sammelson, Susan McDowell   +2 more
doaj   +2 more sources

Delayed Rifampin Administration in the Antibiotic Treatment of Periprosthetic Joint Infections Significantly Reduces the Emergence of Rifampin Resistance

Antibiotics, 2021
Rifampin is one of the most important biofilm-active antibiotics in the treatment of periprosthetic joint infection (PJI), and antibiotic regimens not involving rifampin were shown to have higher failure rates.
Ali Darwich, Franz-Joseph Dally, Mohamad Bdeir, Katharina Kehr, Thomas Miethke, Svetlana Hetjens, Sascha Gravius, Elio Assaf, Elisabeth Mohs   +8 more
doaj   +1 more source

Effect of Cytochrome P450 3A Inhibition and Induction by Itraconazole and Rifampin on Tazemetostat Pharmacokinetics in Patients With Advanced Malignancies. [PDF]

Clin Pharmacol Drug Dev
Abstract This study (NCT04537715) investigated itraconazole (strong cytochrome P450 [CYP] 3A inhibitor) and rifampin (strong CYP3A inducer) on tazemetostat pharmacokinetics. In Part 1, patients received tazemetostat 400 mg orally on Days 1, 15, and 36, and 400 mg twice daily on Days 3‐14 and Days 21‐35.
Chen Y, Teng R, Szanto A, Kapopara A, Bannerji R, Ogier J, Mahalingam D.   +6 more
europepmc   +2 more sources

Treatment Strategy for Rifampin-Susceptible Tuberculosis

New England Journal of Medicine, 2023
Background Tuberculosis is usually treated with a 6-month rifampin-based regimen. Whether a strategy involving shorter initial treatment may lead to similar outcomes is unclear.
N. Paton, Christopher Cousins, Celina Suresh, Erlina Burhan, K. Chew, Victoria B Dalay, Qingshu Lu, T. Kusmiati, V. Balanag, Shu Ling Lee, R. Ruslami, Yogesh Pokharkar, Irawaty Djaharuddin, J. J. Sugiri, Rholine S. Veto, C. Sekaggya-Wiltshire, A. Avihingsanon, R. Sarin, P. Papineni, A. Nunn, A. Crook   +20 more
semanticscholar   +1 more source

A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.

New England Journal of Medicine, 2022
BACKGROUND In patients with rifampin-resistant tuberculosis, all-oral treatment regimens that are more effective, shorter, and have a more acceptable side-effect profile than current regimens are needed.
Bern-Thomas Nyang'wa, Catherine Berry, Emil Kazounis, I. Motta, N. Parpieva, Z. Tigay, V. Solodovnikova, I. Liverko, R. Moodliar, M. Dodd, N. Ngubane, M. Rassool, T. McHugh, M. Spigelman, D. Moore, K. Ritmeijer, P. D. du Cros, Katherine L. Fielding   +17 more
semanticscholar   +1 more source

Comparing the Synergistic and Antagonistic Interactions of Ciprofloxacin and Levofloxacin Combined with Rifampin against Drug-Resistant Staphylococcus aureus: A Time–Kill Assay

Antibiotics, 2023
Background: Treatment of device-related infections by drug-resistant Staphylococcus aureus can be challenging, and combination therapy has been proposed as a potential solution.
Yu Ri Kang, Doo Ryeon Chung, Jae-Hoon Ko, Kyungmin Huh, Sun Young Cho, Cheol-In Kang, Kyong Ran Peck   +6 more
doaj   +1 more source

Deconstructing the Dogma: Systematic Literature Review and Meta-analysis of Adjunctive Gentamicin and Rifampin in Staphylococcal Prosthetic Valve Endocarditis

Open Forum Infectious Diseases, 2022
Background Based primarily on in vitro and animal models, with little data directly addressing patient outcomes, current guidelines recommend treating staphylococcal prosthetic valve endocarditis (PVE) with antibiotic combinations including gentamicin ...
Jonathan H. Ryder, S. Tong, Jason C. Gallagher, E. McDonald, I. Thevarajan, T. Lee, Nicolás W Cortés-Penfield   +6 more
semanticscholar   +1 more source

Rifampin.

American journal of hospital pharmacy, 2021
In 1971, rifampin was approved for treatment of pulmonary tuberculosis and asymptomatic carriers of Neisseria meningitidis. At present, the approved indications remain the same.
Ban Alsayyed
semanticscholar   +1 more source

Comparative evaluation of critical concentrationsfor detecting borderline rifampin resistance in Mycobacterium tuberculosis

Annals of Clinical Microbiology, 2023
Background: Rifampin plays an important role in tuberculosis treatment. In recent years, the introduction of molecular testing techniques has enabled the rapid detection of rifampin resistance, leading to discrepancies with conventional methods.
Chang-Ki Kim, Hee Jae Huh, Jeong Su Park, Taesoung Kim, Jae Han Sohn   +4 more
doaj   +1 more source

Characterizing complex and competing drug–drug interactions between the antiviral regimen of glecaprevir and pibrentasvir with rifampin or carbamazepine

Clinical and Translational Science, 2023
The fixed‐dose combination of the direct acting antivirals glecaprevir (GLE) and pibrentasvir (PIB) is an oral, once‐daily treatment for all six major genotypes of chronic hepatitis C virus infection.
Matthew P. Kosloski, Hong Li, Stanley Wang, Federico Mensa, Jens Kort, Wei Liu   +5 more
doaj   +1 more source